Executive Briefing - Getting to grips with advanced therapies in the EU
This article was originally published in Scrip
Executive Summary
It is now almost a year since new EU rules on the development, evaluation and approval of advanced therapies came into effect. Ian Schofield assesses progress so far and looks at which kinds of products are likely to be coming through the system over the next few years.